Most therapies targeting advanced or metastatic ccRCC are based, as first-line treatment, on the administration of the vascular endothelial growth factor (VEGF) neutralizing antibody termed Bevacizumab. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.